Our Investors Support Bold Initiatives

The 36th Annual J.P. Morgan Healthcare Conference

On Thursday, January 11, 2018 at 11:30am PST, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities. Click the link below to register for the webcast.

Sign up for the Latest Information from Immunomedics

Annual Report

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases.

icon of page with pie chart on it

Explore Resources for Current and Prospective Investors

Explore Resources